Table 1

Demographics and clinical characteristics of the patients with RA

Characteristics of patientsWhole cohort (n=207)
Basic characteristics
 Age at GC initiation (years)55.9±14.5
 Female, % (n)82.6% (171)
 Disease duration (months)24.0 (8.5–96.0)
 DMARD naïve53.1% (110)
 RF positive, % (n)73.2% (55/205)
 Anti-CCP positive, % (n)79.5% (151/190)
Baseline disease activity measures
 TJC284 (2–10)
 SJC283 (1–5)
 PGA, 0–10 cm5 (3–6)
 EGA, 0–10 cm4 (2–6)
 ESR, mm/hour38 (17–60)
 CRP, mg/dL1.30 (0.47–3.74)
 DAS28-ESR4.76 (3.69–5.96)
 SDAI18.7 (10.5–32.4)
 CDAI16.0 (9.0–29.0)
Initial therapy paradigm
 MTX, % (n)75.4% (156)
 LEF, % (n)53.1% (110)
 HCQ, % (n)55.6% (115)
 SSZ, % (n)9.2% (19)
 TII, % (n)13.0% (27)
 NSAIDs, % (n)13.0% (27)
 DMARD combination, % (n)81.1% (163)
 PSL equivalent dose, mg/day10.0 (5.0–10.0)
  • Values are presented as mean (SD) or median (IQR), as applicable.

  • Anti-CCP, anti-cyclic citrullinated peptides; CDAI, clinical disease activity index; CRP, C reactive protein; DAS28, disease activity score based on 28-joint count; DMARDs, disease-modifying antirheumatic drugs; EGA, evaluator’s global assessment; ESR, erythrocyte sedimentation rate; HCQ, hydroxychloroquine; LEF, leflunomide; MTX, methotrexate; PGA, patient’s global assessment; PSL, prednisolone; RF, rheumatoid factor; SDAI, simplified disease activity index; SJC, swollen joint count; SSZ, sulfasalazine; TJC, tender joint count.